With balanced scrutiny, I navigate through the complexities of Retatrutides safety profile, highlighting both its promises and potential challenges
"Additionally, GLP-1 agonists can cause gastrointestinal side effects like nausea, vomiting, and diarrhoea
Lean tirzepatide when: Maximum weight loss is the goal (target greater than 20%) You have T2D with significant insulin resistance (SURPASS-2: 11.2 kg tirzepatide vs 5.7 kg semaglutide) You have moderate-to-severe obstructive sleep apnea with obesity (Zepbound is the only FDA-approved pharmacotherapy) You plateaued on semaglutide after 12+ months You have MASH and need the drug with the strongest resolution data (SYNERGY-NASH: 44 to 62% resolution) Your insurance covers Zepbound or Mounjaro You tolerated the 2.5 mg starting dose well during a prior trial Lean semaglutide when: You have established cardiovascular disease or high CV risk
Handling Injection Site Reactions the Right Way Starting a GLP-1 medication is often a big step, and it's normal to feel a mix of hope and uncertainty, especially when you notice changes in your skin
The gut flora is considered to be a large secretory organ, which produces trimethylamine-N-oxide (TMAO), short-chain fatty acids and secondary bile acids by breaking down the ingested food
doi:10.3389/fnut.2025.1524125 25
